| Title : First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561\/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers - Harding_2022_Liver.Cancer_11_268 |
| Author(s) : Harding JJ , Awada A , Roth G , Decaens T , Merle P , Kotecki N , Dreyer C , Ansaldi C , Rachid M , Mezouar S , Menut A , Bestion EN , Paradis V , Halfon P , Abou-Alfa GK , Raymond E |
| Ref : Liver Cancer , 11 :268 , 2022 |
| Abstract : |
| PubMedSearch : Harding_2022_Liver.Cancer_11_268 |
| PubMedID: 35949290 |
| Title : GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions - Brun_2022_Autophagy_18_678 |
| Author(s) : Brun S , Bestion E , Raymond E , Bassissi F , Jilkova ZM , Mezouar S , Rachid M , Novello M , Tracz J , Hama A , Lalmanach G , Vanderlynden L , Legouffe R , Stauber J , Schubert T , Plach MG , Courcambeck J , Drouot C , Jacquemot G , Serdjebi C , Roth G , Baudoin JP , Ansaldi C , Decaens T , Halfon P |
| Ref : Autophagy , 18 :678 , 2022 |
| Abstract : |
| PubMedSearch : Brun_2022_Autophagy_18_678 |
| PubMedID: 34740311 |
| Gene_locus related to this paper: human-PPT1 |
| Title : GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-beta1 inhibition - Bestion_2020_Ther.Adv.Chronic.Dis_11_2040622320942042 |
| Author(s) : Bestion E , Jilkova ZM , Mege JL , Novello M , Kurma K , Pour STA , Lalmanach G , Vanderlynden L , Fizanne L , Bassissi F , Rachid M , Tracz J , Boursier J , Courcambeck J , Serdjebi C , Ansaldi C , Decaens T , Halfon P , Brun S |
| Ref : Ther Adv Chronic Dis , 11 :2040622320942042 , 2020 |
| Abstract : |
| PubMedSearch : Bestion_2020_Ther.Adv.Chronic.Dis_11_2040622320942042 |
| PubMedID: 32728410 |
| Title : GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma - Brun_2019_Invest.New.Drugs_37_1135 |
| Author(s) : Brun S , Bassissi F , Serdjebi C , Novello M , Tracz J , Autelitano F , Guillemot M , Fabre P , Courcambeck J , Ansaldi C , Raymond E , Halfon P |
| Ref : Invest New Drugs , 37 :1135 , 2019 |
| Abstract : |
| PubMedSearch : Brun_2019_Invest.New.Drugs_37_1135 |
| PubMedID: 30778887 |